Biotechnology

Happiness Development Announces Financial Results for the Six Months Ended September 30, 2021

NANPING, China, Jan. 6, 2022 /PRNewswire/ -- Happiness Development Group Limited ("HAPP" or the "Company"), (NASDAQ: HAPP) aChina-based company engaging in the business of production of nutraceutical and dietary supplements, providing e-commerce sales and e-commerce marketing solutions, and the s...

2022-01-06 21:00 3160

Nuance Pharma acquires Sino Health to further strengthen its commercial capabilities and expand pipelines

SHANGHAI, Jan. 6, 2022 /PRNewswire/ -- Nuance Pharma ("Nuance"or the "Company"), a specialty care focused biopharma with late late-stage clinical programs and existing commercial operations, today announced an agreement with Sino Health Pharmaceutical Limited ("Sino Health") , an affiliated compa...

2022-01-06 14:45 2142

Virtue Diagnostics closes $100 million Series B Funding

SHANGHAI, Jan. 6, 2022 /PRNewswire/ -- Virtue Diagnostics, an innovative IVD company, has just announced closingUS$100 million in Series B funding. Virtue Diagnostics, founded in 2019, is focused on clinical tests forChina and emerging markets. SequoiaChina and Morningside Ventures jointly led th...

2022-01-06 11:01 3586

MingMed to Present at the 40th Annual J.P. Morgan Healthcare Conference

GUANGZHOU, China, Jan. 6, 2022 /PRNewswire/ -- MingMed Biotechnology, a clinical stage company dedicated to developing First-in-Class pharmaceutical products, today announced that Ms.Liza Ko, Chief Financial Officer of the company, has been invited to present at the 40th Annual J.P. Morgan Health...

2022-01-06 09:00 2657

Ascentage Pharma to Present at the J.P. Morgan 40th Annual Healthcare Conference

SUZHOU, China and ROCKVILLE, Md., Jan. 5, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its participation in and presentation at the 40th A...

2022-01-06 08:30 6970

Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation

NEW YORK and SHANGHAI, Jan. 5, 2022 /PRNewswire/ -- Insilico Medicine, a global clinical-stage biotechnology company specializing in the applications of end-to-end artificial intelligence (AI) for drug discovery and development, today announced that the company has nominated preclinical candidate...

2022-01-05 17:00 1976

Antengene to Present at the 40th Annual J.P. Morgan Healthcare Conference

SHANGHAI and HONG KONG, Jan. 5, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncol...

2022-01-05 12:50 2623

IND Approved for Pivotal Clinical Study of HER2 Bispecific Antibody KN026 Combined with Chemotherapy in Gastric Cancer

SUZHOU, China, Jan. 5, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced that the IND application for the pivotal clinical trial (KN026-CSP-001) of the anti-HER2 bispecific antibody KN026 combined with che...

2022-01-05 11:49 4206

Accro Bioscience inks over $50M series B round

SUZHOU, China, Jan. 4, 2022 /PRNewswire/ -- Accro Bioscience (Suzhou) Co., LTD. ("Accro Bioscience"), aChina-based leading biotechnology company, announced that the company has recently raised over$50 million in an oversubscribed Series B round. The financing was led by Hongtai Aplus with partici...

2022-01-05 11:08 1370

COVID-19 Oral Vaccine and Antibody Booster: B. subtilis Spores, Biotechnology Breakthrough by DreamTec

HONG KONG, Jan. 5, 2022 /PRNewswire/ -- Vaccines have been a trending topic ever since the coronavirus outbreak two years ago. DreamTec Research Limited (DreamTec,http://www.dreamtec.hk ) has its major breakthrough in developing a COVID-19 oral vaccine. In its recently pu...

2022-01-05 10:00 2831

BIORCHESTRA, SK Biopharmaceuticals collaborate to develop miRNA-targeted therapeutics

SEOUL, South Korea, Jan. 4, 2022 /PRNewswire/ -- BIORCHESTRA and SK Biopharmaceuticals announcedtoday that they have forged a partnership to research and develop new therapeutic compounds targeting microRNAs [1] (miRNA) for a potential treatment of epilepsy.

2022-01-05 08:07 1692

CAI Announces CEO Succession

INDIANAPOLIS, Jan. 4, 2022 /PRNewswire/ -- CAI, a global consulting company that provides technical, operational consulting, and project management services to life sciences, data centers, and industrial process manufacturing industries, today announcedMichael Martin, CAI President, will succeed ...

2022-01-04 22:33 2294

Origin Agritech Announces Collaboration with BaoDao Feed Ltd. To Commercialize Nutrition Enhanced Corn

BEIJING, Jan. 4, 2022 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), an agriculture technology company, announced today that it has signed a collaborative agreement with BaoDao Feed Ltd. ("BaoDao"), a Chinese feed producer with500 million RMB in annual sales. U...

2022-01-04 22:10 1418

Molecular Stethoscope, Inc. establishes new Corporate Headquarters and Research & Development Laboratories in South San Francisco and appoints Gajus Worthington to its Board of Directors

SOUTH SAN FRANCISCO, Calif., Jan. 4, 2022 /PRNewswire/ -- Molecular Stethoscope, a leading Precision Medicine biotechnology company pioneering the next-generation cf-mRNA Liquid Biopsy, announced today that it has joined Verily Life Sciences ("Verily") partnered laboratory ecosystem inSouth San ...

2022-01-04 19:00 1339

Harbour BioMed Announces Dosing of First Patient of Two Phase I Trials for Next-Generation Anti-CTLA-4 Antibody HBM4003

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Jan. 4, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that, its next generation anti-CTLA-4 fully human heavy-chain only antibody (HCAb), HBM4003, has completed the first dosing of first patient in two phase I tri...

2022-01-04 17:28 1738

Breakthrough Discoveries on Novel Features of Omicron Variant and An Anti-Omicron Antibody JMB2002

SHANGHAI, Jan. 4, 2022 /PRNewswire/ -- Joint research results from Biologics of Jemincare and Shanghai Institute ofMateria Medica (SIMM) of Chinese Academy of Sciences (CAS) confirmed that JMB2002, an anti-SARS-CoV-2 neutralizing antibody (NAb) discovered by Biologics of Jemincare is still effect...

2022-01-04 10:00 2929

TCI's Golden Formula Has Won the Best Plant-Based Functional Product in the World Plant-Based Awards 2021

TAIPEI, Jan. 3, 2022 /PRNewswire/ -- In recent years, there has been a global trend of plant-based health care, which is known as vegetarian food in Taiwan. In the World Plant-Based Awards, jointly organized by FoodBev Media and Plant Based World Expo & Conference, TCI's Golden Formula won the be...

2022-01-04 09:00 1772

Everest Medicines Announces Taiwan FDA Has Accepted New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer

SHANGHAI, Jan. 4, 2022 /PRNewswire/ -- Everest Medicines Limited (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products inAsia, announced today that T...

2022-01-04 08:00 2908

Biosion, Inc. Appoints Anthony Yeh, Ph.D., as Chief Strategy Officer and Head of China BD

NEWARK, Del. and NANJING, China, Jan. 3, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global clinical stage biotechnology company, today announced the appointment of Dr.Anthony Yeh to the position of Chief Strategy Officer and Head ofChina business development (BD), where he will lead corpor...

2022-01-03 18:00 1725

Sihuan Pharmaceutical (0460.HK): Sunshine Life Insurance Leads Investment in Xuanzhu Biopharm

HONG KONG, Jan. 3, 2022 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group"; Hong Kong Stock Exchange stock code: 0460) is pleased to announce that, its subsidiary Xuanzhu...

2022-01-03 14:24 6421
1 ... 152153154155156157158 ... 275

Week's Top Stories